CD79B and diffuse large B-cell lymphoma: ,25,26,27 CD79b is the most clinically advanced target of the two and an anti-CD79b ADC (polatuzumab vedotin, CD79b-MMAE) has been FDA approved for the treatment of diffuse large B cell lymphoma (DLBCL), validating CD79 as a safe and effective target.28